middle.news
How Noxopharm’s HERACLES Trial Safety Win Fuels SOF-SKN™’s Next Phase
9:10am on Wednesday 21st of January, 2026 AEDT
•
Biotechnology
Read Story
How Noxopharm’s HERACLES Trial Safety Win Fuels SOF-SKN™’s Next Phase
9:10am on Wednesday 21st of January, 2026 AEDT
Key Points
Final multiple-dose cohort of HERACLES trial completed
No clinically relevant safety issues detected
High participant compliance with SOF-SKN™ dosing
Phase II-enabling studies and drug scale-up planned
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Noxopharm (ASX:NOX)
OPEN ARTICLE